Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma

Department of General Surgery, Children’s Hospital of Shanghai, Shanghai Jiao Tong University, Shanghai 200030, China

Special Issues: Advanced Big Data Analysis for Precision Medicine

This study intended to gain new insight into the genetic basis underlying ganglioneuroma (GN), ganglioneuroblastoma (GNB), and neuroblastoma (NB). Three fresh-frozen surgically resected tumor tissues (GN1, GNB1, and NB1) and matched blood samples (GN2, GNB2, and NB2) were respectively obtained from three pediatric patients with GN, GNB, and NB. After exome sequencing, we predicted the somatic single nucleotide variants (SNV) and insertion and deletion (InDel), and screened the predisposing genes. Finally, we detected and filtered the fusion gene using Fusionmap. Exome sequencing identified 815, 985, and 884 somatic SNV, and 56, 43, and 34 InDel for GN, NB, and GNB respectively. Total 29, 19 and 37 predisposing genes were identified from GN, GNB and NB samples, such as PIK3CA (GN), MUC4 (GN), PML (NB), TFR2 (GNB), and MAX (GNB). Additionally, four common fusion genes, such as HOXD11-AGAP3 and SAMD1-CDC42EP5, were identified from three tumor samples. Moreover, SAMD1-CDC42EP5 was also a common fusion position in three blood samples. These previously unrecognized predisposing genes, such as PIK3CA, MUC4, PML, TFR2 and MAX, and fusion genes, like HOXD11-AGAP3, and SAMD1-CDC42EP5 may have the potential to impact the progression and development of neuroblastic tumors.
  Figure/Table
  Supplementary
  Article Metrics

Keywords ganglioneuroma; ganglioneuroblastoma; neuroblastoma; exome sequencing; predisposing gene

Citation: Wei Wu, Weijue Xu, Jiangbin Liu, Jun Sun, Yimin Huang, Zhibao Lv. Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma. Mathematical Biosciences and Engineering, 2019, 16(6): 7217-7229. doi: 10.3934/mbe.2019362

References

  • 1. G. J. Lonergan, C. M. Schwab, E. S. Suarez, et al., From the archives of the AFIP: Neuroblastoma, ganglioneuroblastoma and ganglioneuroma: Radiologic-pathologic correlation 1, Radiographics, 22 (2002), 911–934.
  • 2. C. C. Hsiao, C. C. Huang, J. M. Sheen, et al., Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma, Modern pathol., 18 (2005), 656–662.
  • 3. J. G. Gurney, R. K. Severson, S. Davis, et al., Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type, Cancer, 75 (1995), 2186–2195.
  • 4. J. Brossard, M. L. Bernsteinand and B. Lemieux, Neuroblastoma: an enigmatic disease, Brit. Med. Bull., 52 (1996), 787–801.
  • 5. A. G. Knudson, Mutation and cancer: Statistical study of retinoblastoma, Proc. Natl. Acad. Sci. USA 68 (1971), 820–823.
  • 6. H. Carén, F. Abel, P. Kogner, et al., High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours, Biochem. J., 416 (2008), 153–159.
  • 7. Y. P. Mossé, M. Laudenslager, L. Longo, et al., Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, 455 (2008), 930–935.
  • 8. I. Janoueix-Lerosey, D. Lequin, L. Brugières, et al., Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, 455 (2008), 967–970.
  • 9. K. Sossey-Alaoui, G. Su, E. Malaj, et al., WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1; 13)(q21; q12) chromosome translocation in a patient with ganglioneuroblastoma, Oncogene, 21 (2002), 5967.
  • 10. X. Wei, V. Walia, J. C. Lin, et al., Exome sequencing identifies GRIN2A as frequently mutated in melanoma, Nat. Genet., 43 (2011), 442–446.
  • 11. I. Varela, P. Tarpey, K. Raine, et al., Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, Nature, 469 (2011), 539–542.
  • 12. G. L. Dalgliesh, K. Furge, C. Greenman, et al., Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes, Nature, 463 (2010), 360–363.
  • 13. R. D. Morin, N. A. Johnson, T. M. Severson, et al., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin, Nat. Genet., 42 (2010), 181–185.
  • 14. H. Liand R. Durbin, Fast and accurate short read alignment with Burrows–Wheeler transform, Bioinformatics, 25 (2009), 1754–1760.
  • 15. H. Li, B. Handsaker, A. Wysoker, et al., The sequence alignment/map format and SAMtools, Bioinformatics, 25 (2009), 2078–2079.
  • 16. D. C. Koboldt, Q. Zhang, D. E. Larson, et al., VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing, Genome Res., 22 (2012), 568–576.
  • 17. H. Ge, K. Liu, T. Juan, et al., FusionMap: Detecting fusion genes from next-generation sequencing data at base-pair resolution, Bioinformatics, 27 (2011), 1922–1928.
  • 18. Y. Samuels and V. E. Velculescu, Oncogenic mutations of PIK3CA in human cancers, Cell Cycle, 3 (2004), 1221–1224.
  • 19. S. Kang, A. G. Baderand P. K. Vogt, Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic, P. Natl. Acad. Sci. USA, 102 (2005), 802–807.
  • 20. K. E. Bachman, P. Argani, Y. Samuels, et al., The PIK3CA gene is mutated with high frequency in human breast cancers, Cancer Biol. Ther., 3 (2004), 772–775.
  • 21. Y. Samuels, Z. Wang, A. Bardelli, et al., High frequency mutations of the PIK3CA gene in human cancers, Science, 304 (2004), 554.
  • 22. S. K. Srivastava, A. Bhardwaj, S. Singh, et al., MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells, Carcinogenesis, 32 (2011), 1832–1839.
  • 23. R. Bernardi and P. P. Pandolfi, Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies, Nat. Rev. Mol. Cell Bio., 8 (2007), 1006.
  • 24. S. Hirohashi and Y. Kanai, Cell adhesion system and human cancer morphogenesis, Cancer Sci., 94 (2003), 575–581.
  • 25. H. Kawabata, R. E. Fleming, D. Gui, et al., Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis, Blood, 105 (2005), 376–381.
  • 26. A. Calzolari, I. Oliviero, S. Deaglio, et al., Transferrin receptor 2 is frequently expressed in human cancer cell lines, Blood Cell Mol. Dis., 39 (2007), 82.
  • 27. B. Amati and H. Land, Myc-Max-Mad: A transcription factor network controlling cell cycle progression, differentiation and death, Curr. Opin. Genet. Dev., 4 (1994), 102–108.
  • 28. I. Cominoméndez, F. J. Graciaaznárez, F. Schiavi, et al., Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma, Nat. Genet., 43 (2011), 663.
  • 29. F. Vanoli, M. Tomishima, W. Feng, et al., CRISPR-Cas9-guided oncogenic chromosomal translocations with conditional fusion protein expression in human mesenchymal cells, P. Natl. Acad. Sci. USA, (2017).
  • 30. T. Taketani, T. Taki, N. Shibuya, et al., The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15), Cancer Res., 62 (2002), 33.
  • 31. D. J. Sharpe, K. S. Orr, M. Moran, et al., POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer, Oncotarget, 5 (2014), 8803–8815.
  • 32. S. Bhatlekar, J. Z. Fieldsand B. M. Boman, HOX genes and their role in the development of human cancers, J. Mol. Med., 92 (2014), 811–823.
  • 33. E. Langenfeld, Y. Kongand J. Langenfeld, Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5, Oncogene, 25 (2006), 685.
  • 34. X. Liu, J. Yue, R. S. Frey, et al., Transforming growth factor β signaling through Smad1 in human breast cancer cells, Cancer Res., 58 (1998), 4752–4757.
  • 35. J. Yue, R. S. Frey and K. M. Mulder, Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFβ, Oncogene, 18 (1999), 2033.
  • 36. M. Kretzschmar, J. Doody and J. Massagu, Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1, Nature, 389 (1997), 618.
  • 37. D. S. Hirsch, D. M. Pirone and P. D. Burbelo, A New Family of Cdc42 Effector Proteins, CEPs, Function in Fibroblast and Epithelial Cell Shape Changes, J. Biol. Chem., 276 (2001), 875–883.
  • 38. M. Hu, J. Yao, L. Cai, et al., Distinct epigenetic changes in the stromal cells of breast cancers, Nat. Genet., 37 (2005), 899–905.

 

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved